Table 3.
Univariate and multivariable analyses of EFS in patients not achieving pCR.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Characteristic | HR (95% CI) | P-values | HR (95%CI) | P-values |
| Age at diagnosis | ||||
| <50 | Ref | |||
| ≥50 | 0.7 (0.31–1.48) | 0.34 | ||
| Genetic mutation | ||||
| No | Ref | |||
| Yes | 0.9 (0.6–1.6) | 0.96 | ||
| BMI | ||||
| <25 | Ref | Ref | ||
| ≥25 | 0.32 (0.12–0.8) | 0.021 | 0.67 (0.23–1.94) | 0.46 |
| Bilateral disease | ||||
| No | Ref | |||
| Yes | 4.3 (1.3–14.5) | 0.01 | ||
| Multifocal disease | ||||
| No | Ref | Ref | ||
| Yes | 3.2 (1.5–6.7) | 0.002 | 3.77 (1.45–9.61) | 0.005 |
| MRI | ||||
| No | Ref | |||
| Yes | 0.7 (0.3–1.4) | 0.36 | ||
| Histology on tumor biopsy | ||||
| Ductal | Ref | |||
| Other | 0.8 (0.19–3.4) | 0.78 | ||
| Grade on tumor biopsy | ||||
| II | Ref | |||
| III | 1.001 (1–1.001) | 0.19 | ||
| Ki-67 on tumor biopsy | ||||
| <20 | Ref | |||
| ≥20 | 0.9 (0.99–1.006) | 0.66 | ||
| Clinical T stage | ||||
| T1–T2 | Ref | Ref | ||
| T3–T4 | 3.4 (1.4–9) | 0.02 | 1.35 (0.49–2.36) | 0.07 |
| HER2 low on tumor biopsy | ||||
| No | Ref | |||
| Yes | 0.7 (0.4–1.1) | 0.16 | ||
| Clinical N stage | ||||
| N0 | Ref | Ref | ||
| N+ | 2.4 (1.1–5) | 0.02 | 3.77 (1.48–9.63) | 0.06 |
| Time NACT surgery | ||||
| <30 days | Ref | |||
| ≥30 days | 0.9 (0.94–1) | 0.13 | ||
| Type surgery | ||||
| Conservative | Ref | |||
| Mastectomy | 1.8 (0.8–4.5) | 0.14 | ||
| SLNB | ||||
| No | Ref | |||
| Yes | 1 (0.97–1.007) | 1 | ||
| LN assessment | ||||
| ≤10 | Ref | |||
| >10 | 1.01 (1.001–1.04) | 0.05 | ||
| Type of NACT | ||||
| Anthra + tax | Ref | |||
| Anthra/Tax | 2.98 (0.87–10.1) | 0.80 | ||
| Plat + other agents | 0.41 (0.14–1.13) | 0.85 | ||
| Anthra/tax | Ref | |||
| Plat + other agents | 0.05 (0.01–1.009) | 0.06 | ||
| Residual cancer burden | ||||
| I | Ref | |||
| II | 21.8 (0.001–>100) | 0.63 | ||
| III | 0.58 (0.33–089) | 0.04 | ||
| II | Ref | Ref | ||
| III | 8.57 (3.58–21.3) | 0.001 | 3.04 (1.09–9.9) | 0.04 |
| TILs on residual tumor | ||||
| ≥30 | Ref | |||
| <30 | 3.48 (0.96–12.5) | 0.06 | ||
| Tumor grade on residual tumor | ||||
| II | Ref | |||
| III | 4.2 (1.4–12) | 0.05 | ||
| Ki-67 on residual tumor | ||||
| <20 | Ref | |||
| ≥20 | 0.61 (0.09–3.36) | 0.81 | ||
| Ki-67 pre- vs. post-NACT | ||||
| Stable/increased | Ref | |||
| Decreased | 1 (0.99–1.01) | 0.72 | ||
| LVSI on residual tumor | ||||
| No | Ref | |||
| Yes | 11 (3–36) | 0.001 | ||
| Adjuvant CHT | ||||
| No | Ref | Ref | ||
| Yes | 2.9 (1.5–6) | 0.03 | 1.89 (0.21–2.14) | 0.54 |
| Time surgery-RT | ||||
| ≤90 days | Ref | |||
| >90 days | 0.99 (0.99–1) | 0.09 | ||
BMI, body mass index; MRI, magnetic resonance imaging; T, tumor; HER2, human epidermal growth factor receptor; N, node; NACT, neoadjuvant chemotherapy; SLNB, sentinel lymph node biopsy; LN, lymph node; Anthra, anthracycline-based chemotherapy; Tax, taxane-based chemotherapy; Plat, platinum-based chemotherapy; LVSI, lymphovascular space invasion; CHT, chemotherapy; RT, radiotherapy.